BioStem Technologies, Inc. (OTC PINK: BSEM) a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, today announced that its subsidiary, BioStem Life Sciences has been awarded the prestigious accolade of accreditation by the American Association of Tissue Banks® (AATB®). BioStem Life Sciences is now accredited for Donor Eligibility Assessment, Processing, Storage, and Distribution of Birth Tissue and Cellular Tissue for Transplantation. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]
Contract Development & Manufacturing (CDMO):
B-MoGen’s ISO 7 cleanrooms now open for business
B-MoGen Biotechnologies, a unit of Bio-Techne, is proud to announce new cGMP cellular therapy manufacturing capacity for Phase I and Phase II clinical trials.
Minneapolis, June 15, 2020 — Are you looking for a CDMO to process your Phase I/II clinical trials or to manufacture GMP grade engineered mammalian cells? If you need this service now and need it at a reasonable cost, B-MoGen’s new clean room facility became fully operational as of May 1, 2020. B-MoGen now offers process development for any gene modified therapy, cGMP patient processing for Phase I and Phase II clinical trials, and cGMP manufacturing of iPSC cell lines.
B-MoGens state of the art 6,000 square foot cGMP facility is strategically located in Minneapolis, MN, USA. Its US-based suites currently comply with ISO Class 7 (Class 10,000) classification to meet U.S. requirements.
View video footage of the B-MoGen facility:
For more information visit:
Email: [email protected]
What questions do you have for B-MoGen about their CDMO services for cellular therapy manufacturing? Ask them in the comments below.
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020– Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs. [Read more…]
Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.
What is an extra-cellular vesicle?
EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]